Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABL103 in advanced solid tumors
NCT06126666Phase 1Recruiting
- Sponsor
- ABL Bio
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ABL103 in solid tumor, sponsored by ABL Bio. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events and 2 more. Started Nov 2023; status: recruiting.
02
Drugs
ABL103
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06126666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126666.